Tadalafil Tablet, Film Coated
Product Images NDC 71821-007

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71821-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vkt Pharma Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil Tablets Figure 1)

A set of four line graphs showing the difference in blood pressure (mmHg) between tadalafil and placebo over time (hours). The graphs display standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes, with data points and error bars indicating variability at each time point.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil Tablets Figure 2)

Two line graphs showing changes in systolic blood pressure (mmHg) over time (hours post-dose) up to 24 hours for tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The top graph depicts standing systolic blood pressure, while the bottom graph shows supine systolic blood pressure, each comparing the two treatment groups with measurements ranging from -20 to 10 mmHg.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil Tablets Figure 3)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours following administration of tadalafil or placebo combined with doxazosin. Four curves represent 20 mg tadalafil at 08:00 and 20:00 with 8 mg doxazosin, and placebo at these times with 8 mg doxazosin, showing differences in blood pressure response over time.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil Tablets Figure 4)

A line graph showing plasma tadalafil concentration (μg/L) on the y-axis over time in hours on the x-axis. It compares plasma levels after a single 20-mg dose, a single 5-mg dose, and a once-daily 5-mg dose following 5 consecutive days of administration, with plotted points and error bars indicating variability across time points.*

FDA Label Image

Tadalafil-tablets-figure-5 (Tadalafil Tablets Figure 5)

A line graph comparing the change from baseline in IIEF total score over 12 weeks of treatment between tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change in IIEF total score, with trends indicating greater improvement for tadalafil 5 mg versus placebo, with statistical significance at p<0.01.*

FDA Label Image

Tadalafil-tablets-figure-6 (Tadalafil Tablets Figure 6)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration, comparing tadalafil 5 mg to placebo. The plot shows that tadalafil 5 mg leads to a greater reduction in IPSS score compared to placebo, with significance indicated at p<0.01.*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil Tablets Figure 7)

Line graph comparing least-squares mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride. The Y-axis shows LS mean change values, and the X-axis represents weeks of therapy (0, 4, 12, 26). Data points highlight statistically significant differences (p<0.001 and p<0.05) between treatment groups at certain time points.*

FDA Label Image

Tadalafil-tablets-figure-8 (Tadalafil Tablets Figure 8)

A line graph depicting change from baseline in IPSS total score over treatment duration in weeks. It compares tadalafil 5 mg with placebo, showing a greater decrease in score for tadalafil across 12 weeks, with statistically significant differences marked (p<0.01). The x-axis is treatment duration (weeks); y-axis is change from baseline in IPSS total score.*

FDA Label Image

Chemical Structure (Tadalafil Tablets Structure)

Chemical structure of tadalafil depicted as a molecular diagram illustrating the compound's rings, bonds, and functional groups.*

FDA Label Image

Tadalafin Tablets,usp,10 mg (NDC-71821-008-01)

Label for tadalafil tablets USP 10 mg, film-coated oral tablets by VKT Pharma Private Limited. The carton contains 30 tablets, indicated for prescription use only. Label includes storage instructions, a barcode, and manufacturer details from Srikakulam, India.*

FDA Label Image

Tadalafin Tablets,usp,20 mg (NDC-71821-009-01)

Tadalafil Tablets, USP 20 mg film-coated tablets label with 30 tablets. Includes NDC 71821-009-01, usage warnings, storage instructions, and manufacturer information for VKT Pharma Private Limited, Srikakulam, India. Label instructs not to split tablets and to take the entire dose.*

FDA Label Image

Tadalafin Tablets,usp,2.5 mg (NDC-71821-006-01 Blister Label)

Tadalafil Tablets USP 2.5 mg film-coated tablets packaging label by VKT Pharma Private Limited. The label indicates a quantity of 15 tablets, with storage instructions and a barcode. It includes usage and dosage info along with a warning to keep out of reach of children.*

FDA Label Image

Tadalafin Tablets,usp,2.5 mg (NDC-71821-006-01)

Tadalafil Tablets, USP 2.5 mg film-coated oral tablets packaging label from VKT Pharma Private Limited. The package contains 30 tablets divided into 2 blisters of 15 tablets each. The label states the medication is for once daily use, with instructions that tablets should not be split and the entire dose should be taken. The label includes the NDC code 71821-006-01 and manufacturer information from India.*

FDA Label Image

Tadalafin Tablets,usp,5 mg (NDC-71821-007-02)

Label for tadalafil tablets USP 5 mg oral film-coated tablets from VKT Pharma Private Limited. The label indicates a 30-tablet count with directions that tablets should not be split and stored at controlled room temperature. The label includes barcode, manufacturer details in India, and storage and warning information.*

FDA Label Image

Tadalafin Tablets,usp,5 mg (NDC-71821-007-01)

Tadalafil Tablets, USP 5 mg film-coated oral tablets by VKT Pharma Private Limited. The packaging contains 15 tablets, with dosage instructions visible on the label. The label includes storage guidelines, warnings to keep out of reach of children, manufacturer information, and bar code. The label features the VKT logo and National Drug Code (NDC) 71821-007-01.*

FDA Label Image

Tadalafin Tablets,usp,5 mg (NDC-71821-007-01)

Packaging label for Tadalafil Tablets, USP 5 mg oral film-coated tablets by VKT Pharma Private Limited. The carton contains 30 tablets, supplied as 2 blisters of 15 tablets each. The label states the product is for once daily use and includes instructions that tablets should not be split and the entire dose should be taken. The NDC number 71821-007-01 and a barcode are also visible.*

FDA Label Image

Vkt-pharma-logo-1 (Vkt Pharma Logo 1)

FDA Label Image

Vkt-pharma-logo (Vkt Pharma Logo 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.